Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

NJIRA L LUGOGO

Allopathic & Osteopathic Physicians Internal Medicine Pulmonary Disease

NPI
1649219734
CMS profile
210573
Location
ANN ARBOR, MI

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2022 · Entire year

$88,290.39

67 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2022 · entire year · sorted by reported total

By paying entity

PY2022 · entire year · sorted by reported total

Paying entityAmountRecords
GlaxoSmithKline, LLC. $38,270.92 33
AstraZeneca Pharmaceuticals LP $19,153.19 12
Teva Pharmaceuticals USA, Inc. $13,052.14 3
Regeneron Pharmaceuticals, Inc. $7,622.80 4
GENZYME CORPORATION $4,361.00 1
Regeneron Healthcare Solutions, Inc. $3,060.67 10
Genentech USA, Inc. $2,700.00 1
Amgen Inc. $57.08 2
Genentech, Inc. $12.59 1

Page 2 of 2; records 51–67 of 67 matching records. This page contains 17 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

NJIRA L LUGOGO

NPI 1649219734 · CMS profile ID 210573

Allopathic & Osteopathic Physicians / Internal Medicine / Pulmonary Disease

ANN ARBOR, MI

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 2; records 51–67 of 67 matching records. This page contains 17 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1649219734?year=2022&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
NJIRA L LUGOGO, NPI 1649219734, CMS profile ID 210573. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–67 of 67 matching records. This page contains 17 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1649219734?year=2022&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
APA 7
IndustryPayments. (2026). NJIRA L LUGOGO, NPI 1649219734, CMS profile ID 210573. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–67 of 67 matching records. This page contains 17 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1649219734?year=2022&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
Bluebook
NJIRA L LUGOGO, NPI 1649219734, CMS profile ID 210573, IndustryPayments, General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–67 of 67 matching records. This page contains 17 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c. https://industrypayments.org/provider/npi-1649219734?year=2022&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2022 · Physicians and non-physician practitioners · CMS publication 2026-06-30

67 matching records · $88,290.39 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 67 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–67 of 67.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
AstraZeneca Pharmaceuticals LP $57.0005/18/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 915255849 CMS
AstraZeneca Pharmaceuticals LP $124.0005/18/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 915867875 CMS
AstraZeneca Pharmaceuticals LP $50.0005/16/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 914753091 CMS
AstraZeneca Pharmaceuticals LP $30.0005/16/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 915547303 CMS
Teva Pharmaceuticals USA, Inc. $8.5505/16/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 954713297 CMS
Amgen Inc. $28.5405/15/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 939226161 CMS
Amgen Inc. $28.5405/15/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 939226163 CMS
GlaxoSmithKline, LLC. $1,300.0005/03/2022 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 945075549 CMS
Regeneron Healthcare Solutions, Inc. $2,000.0003/25/2022 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 927265607 CMS
Regeneron Pharmaceuticals, Inc. $1,216.0003/25/2022 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 927745839 CMS
Regeneron Pharmaceuticals, Inc. $1,884.8003/25/2022 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 927745844 CMS
AstraZeneca Pharmaceuticals LP $2,942.5003/10/2022 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 914803125 CMS
AstraZeneca Pharmaceuticals LP $6,981.0002/17/2022 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 914626959 CMS
AstraZeneca Pharmaceuticals LP $1,872.5001/27/2022 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 914845891 CMS
AstraZeneca Pharmaceuticals LP $1,074.0001/27/2022 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 915465883 CMS
Teva Pharmaceuticals USA, Inc. $13,000.0001/25/2022 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 954713261 CMS
GlaxoSmithKline, LLC. $671.1301/11/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 945075551 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $88,484.69 119
PY2020 $69,221.75 20
PY2021 $42,791.40 17
PY2022 $88,290.39 67
PY2023 $173,062.01 100
PY2024 $135,779.52 105
PY2025 $143,281.81 107

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $32,338.36 48
PY2025 Principal investigator $1,373,743.27 487
PY2024 Recipient $25,864.39 56
PY2024 Principal investigator $1,656,940.36 429
PY2023 Recipient $6,083.82 22
PY2023 Principal investigator $1,480,274.28 230
PY2022 Recipient $6,369.01 15
PY2022 Principal investigator $3,011,015.59 84
PY2021 Principal investigator $2,572,809.14 60
PY2020 Principal investigator $1,587,393.06 25
PY2019 Principal investigator $493,855.47 29

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

535 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 PFIZER INC. $39,830.00 12/25/2025 Covered Recipient Teaching Hospital
Univ Of Mi Hospitals & Hlth Ctrs
A PHASE 2 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED PARALLELGROUP DOSERANGING STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF PF07275315 IN ADULT PARTICIPANTS WITH INADEQUATELY CONTROLLED MODERATETOSEVERE ASTHMA No dispute reported 06/30/2026 1228720285
Principal investigator 1 GlaxoSmithKline, LLC. $1,133.10 12/19/2025 Non-covered Recipient Entity
THE REGENTS OF THE UNIVERSITY OF MICHIGAN
A PHASE 3, 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA No dispute reported 06/30/2026 1192165859
Principal investigator 1 SANOFI US SERVICES INC. $917.00 12/15/2025 Covered Recipient Teaching Hospital
Univ Of Mi Hospitals & Hlth Ctrs
An Open Label Extension Study to Evaluate the Long-term Safety and Efficacy of Subcutaneous Lunsekimig in Adult Participants With Moderatetosevere Asthma Who Participated in Study DRI16762 No dispute reported 06/30/2026 1226134219
Principal investigator 1 GlaxoSmithKline, LLC. $1,229.85 12/12/2025 Non-covered Recipient Entity
THE REGENTS OF THE UNIVERSITY OF MICHIGAN
A PHASE 3, 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA No dispute reported 06/30/2026 1192167038
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $39.99 12/12/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184138873
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $32.25 12/12/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184138875
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $224.46 12/12/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184138877
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $32.25 12/12/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184138879
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $32.25 12/12/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184138881
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $25.80 12/12/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184138883
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $39.99 12/12/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184138885
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $34.83 12/12/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184138887
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $18.06 12/12/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184138889
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $39.99 12/12/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184138891
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $32.25 12/12/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184138893
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $32.25 12/12/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184138895
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $32.25 12/12/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184138897
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $32.25 12/12/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184138899
Principal investigator 1 Genentech, Inc. $3,550.00 12/03/2025 Covered Recipient Teaching Hospital
Univ Of Mi Hospitals & Hlth Ctrs
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211560273
Principal investigator 1 GlaxoSmithKline, LLC. $4,424.40 11/25/2025 Non-covered Recipient Entity
THE REGENTS OF THE UNIVERSITY OF MICHIGAN
A PHASE 3, 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA No dispute reported 06/30/2026 1192163354
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $608.56 11/17/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184138845
Principal investigator 1 SANOFI US SERVICES INC. $6,228.00 11/17/2025 Non-covered Recipient Entity
The Regents Of The University Of Michigan
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose Ranging Study to Assess the Efficacy, Safety, and Tolerability of Subcutaneous SAR443765 in Adult Participants With Moderate to Severe Asthma No dispute reported 06/30/2026 1226157494
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $33.54 11/12/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184138813
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $25.80 11/12/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184138815
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $25.80 11/12/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184138817
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $37.41 11/12/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184138819
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $224.46 11/12/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184138821
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $77.00 11/12/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184138823
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $32.25 11/12/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184138825
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $45.15 11/12/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184138827
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $50.31 11/12/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184138829
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $37.41 11/12/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184138831
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $37.41 11/12/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184138833
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $33.54 11/12/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184138835
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $967.50 11/12/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184138837
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $224.46 11/12/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184138839
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $28.38 11/12/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184138841
Principal investigator 1 GENZYME CORPORATION $591.52 11/10/2025 Covered Recipient Teaching Hospital
Univ Of Mi Hospitals & Hlth Ctrs
A Randomized, Double-Blind, Placebo Controlled Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Patients With Uncontrolled Moderate to Severe Asthma No dispute reported 06/30/2026 1226134184
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $7,353.00 11/10/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184138807
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $39.99 11/10/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184138809
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $32.25 11/10/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184138811
Principal investigator 1 SANOFI US SERVICES INC. $5,641.50 11/04/2025 Covered Recipient Teaching Hospital
Univ Of Mi Hospitals & Hlth Ctrs
An Open Label Extension Study to Evaluate the Long-term Safety and Efficacy of Subcutaneous Lunsekimig in Adult Participants With Moderatetosevere Asthma Who Participated in Study DRI16762 No dispute reported 06/30/2026 1226134181
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $608.56 11/03/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184138801
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $608.56 11/03/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184138803
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $608.56 11/03/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184138805
Recipient GENZYME CORPORATION $1,250.00 10/27/2025 Covered Recipient Physician Randomized, Double Blind, Placebo Controlled Study to Evaluate the Effect of Dupilumab on Airway Inflammation Through Assessments of Lung Function, Mucus Plugging and Other Lung Imaging Parameters in Patients With Asthma No dispute reported 06/30/2026 1226119573
Principal investigator 1 GENZYME CORPORATION $2,998.00 10/27/2025 Covered Recipient Teaching Hospital
Univ Of Mi Hospitals & Hlth Ctrs
A Randomized, Double-Blind, Placebo Controlled Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Patients With Uncontrolled Moderate to Severe Asthma No dispute reported 06/30/2026 1226134129
Principal investigator 1 Genentech, Inc. $25,266.00 10/17/2025 Covered Recipient Teaching Hospital
Univ Of Mi Hospitals & Hlth Ctrs
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211560244
Principal investigator 1 GlaxoSmithKline, LLC. $3,240.90 10/17/2025 Non-covered Recipient Entity
THE REGENTS OF THE UNIVERSITY OF MICHIGAN
A PHASE 3, 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA No dispute reported 06/30/2026 1192165844
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $33.54 10/15/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184138651
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $37.41 10/15/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184138653
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $25.80 10/15/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184138655
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $77.00 10/15/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184138657
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $25.80 10/15/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184138659
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $33.54 10/15/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184138661
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $37.41 10/15/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184138663
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $224.46 10/15/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184138665
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $25.80 10/15/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184138667
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $45.15 10/15/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184138669
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $37.41 10/15/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184138671
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $25.80 10/15/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184138673
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $25.80 10/15/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184138675
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $28.38 10/15/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184138677
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $33.54 10/15/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184138679
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $77.00 10/15/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184138681
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $33.54 10/15/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184138683
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $32.25 10/15/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184138685
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $25.80 10/15/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184138687
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $77.00 10/15/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184138689
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $37.41 10/15/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184138691
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $37.41 10/15/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184138693
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $37.41 10/15/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184138695
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $37.41 10/15/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184138697
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $224.46 10/15/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184138699
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $77.00 10/15/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184138701
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $77.00 10/15/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184138703
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $33.54 10/15/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184138705
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $224.46 10/15/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184138707
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $77.00 10/15/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184138709
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $37.41 10/15/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184138711
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $37.41 10/15/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184138713
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $28.38 10/15/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184138715
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $33.54 10/15/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184138717
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $25.80 10/15/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184138719
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,500.00 10/15/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184138721
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $77.00 10/15/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184138723
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $25.80 10/15/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184138725
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $37.41 10/15/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184138727
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $50.31 10/15/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184138729
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $37.41 10/15/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184138731
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $37.41 10/15/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184138733
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $37.41 10/15/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184138735
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $28.38 10/15/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184138737
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $33.54 10/15/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184138739
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $37.41 10/15/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184138741
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $37.41 10/15/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184138743
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $28.38 10/15/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184138745
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $33.54 10/15/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184138747
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $33.54 10/15/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184138749
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $37.41 10/15/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184138751
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $77.00 10/15/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184138753
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $37.41 10/15/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184138755
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $77.00 10/15/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184138757
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $45.15 10/15/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184138759
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $28.38 10/15/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184138761
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $196.08 10/15/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184138763
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $37.41 10/15/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184138765
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $28.38 10/15/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184138767
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $28.38 10/15/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184138769
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $28.38 10/15/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184138771
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $32.25 10/15/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184138773
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $50.31 10/15/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184138775
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $25.80 10/15/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184138777
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $33.54 10/15/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184138779
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $25.80 10/15/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184138781
Principal investigator 1 SANOFI US SERVICES INC. $6,393.44 10/14/2025 Covered Recipient Teaching Hospital
Univ Of Mi Hospitals & Hlth Ctrs
An Open Label Extension Study to Evaluate the Long-term Safety and Efficacy of Subcutaneous Lunsekimig in Adult Participants With Moderatetosevere Asthma Who Participated in Study DRI16762 No dispute reported 06/30/2026 1226134119
Principal investigator 1 SANOFI US SERVICES INC. $3,140.10 10/06/2025 Non-covered Recipient Entity
The Regents Of The University Of Michigan
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose Ranging Study to Assess the Efficacy, Safety, and Tolerability of Subcutaneous SAR443765 in Adult Participants With Moderate to Severe Asthma No dispute reported 06/30/2026 1226157468
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $608.56 10/03/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184138643
Principal investigator 1 GlaxoSmithKline, LLC. $5,216.85 10/02/2025 Non-covered Recipient Entity
THE REGENTS OF THE UNIVERSITY OF MICHIGAN
A PHASE 3, 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA No dispute reported 06/30/2026 1192165847
Recipient Regeneron Pharmaceuticals, Inc. $1,459.29 10/01/2025 Covered Recipient Physician DUPIXENT CLINICAL DEVELOPMENT PROGRAM No dispute reported 06/30/2026 1184119827
Recipient GENZYME CORPORATION $500.00 09/30/2025 Covered Recipient Physician A Randomized, Double Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Dupilumab in Patients With Persistent Asthma No dispute reported 06/30/2026 1226119553
Recipient GENZYME CORPORATION $250.00 09/30/2025 Covered Recipient Physician A Randomized, Double Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Dupilumab in Patients With Persistent Asthma No dispute reported 06/30/2026 1226119564
Recipient GENZYME CORPORATION $500.00 09/29/2025 Covered Recipient Physician A Randomized, Double Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Dupilumab in Patients With Persistent Asthma No dispute reported 06/30/2026 1226119569
Recipient GENZYME CORPORATION $250.00 09/28/2025 Covered Recipient Physician A Randomized, Double Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Dupilumab in Patients With Persistent Asthma No dispute reported 06/30/2026 1226119561
Principal investigator 1 AstraZeneca UK Limited $47,617.00 09/24/2025 Covered Recipient Teaching Hospital
Univ Of Mi Hospitals & Hlth Ctrs
BRISOTE A Multicentre Randomised DoubleBlind Parallel Group ActiveControlled Phase 3b Study to Evaluate the Efficacy and Safety of Benralizumab 30 mg SC in Eosinophilic Asthma Patients Uncontrolled on Medium Dose Inhaled Corticosteroid Plus Long acting 2 Agonist No dispute reported 06/30/2026 1185539665
Principal investigator 1 SANOFI US SERVICES INC. $3,885.00 09/22/2025 Non-covered Recipient Entity
The Regents Of The University Of Michigan
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose Ranging Study to Assess the Efficacy, Safety, and Tolerability of Subcutaneous SAR443765 in Adult Participants With Moderate to Severe Asthma No dispute reported 06/30/2026 1226157455
Principal investigator 1 SANOFI US SERVICES INC. $6,732.00 09/08/2025 Non-covered Recipient Entity
The Regents Of The University Of Michigan
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose Ranging Study to Assess the Efficacy, Safety, and Tolerability of Subcutaneous SAR443765 in Adult Participants With Moderate to Severe Asthma No dispute reported 06/30/2026 1226157430
Principal investigator 1 GlaxoSmithKline, LLC. $2,103.30 09/03/2025 Non-covered Recipient Entity
THE REGENTS OF THE UNIVERSITY OF MICHIGAN
A PHASE 3, 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA No dispute reported 06/30/2026 1192165866
Recipient Regeneron Pharmaceuticals, Inc. $825.43 09/01/2025 Covered Recipient Physician REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184119823
Recipient Regeneron Pharmaceuticals, Inc. $638.44 09/01/2025 Covered Recipient Physician REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184119825
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $96.75 08/28/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184138551
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $193.50 08/28/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184138553
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $32.25 08/28/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184138555
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $193.50 08/28/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184138557
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $64.50 08/28/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184138559
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $64.50 08/28/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184138561
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $418.00 08/28/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184138563
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $225.75 08/28/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184138565
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $225.75 08/28/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184138567
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $32.25 08/28/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184138569
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $65.00 08/28/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184138571
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $97.50 08/28/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184138573
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $32.25 08/28/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184138575
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $129.00 08/28/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184138577
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $129.00 08/28/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184138579
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $64.50 08/28/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184138581
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $96.75 08/28/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184138583
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $96.75 08/28/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184138585
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $96.75 08/28/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184138587
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $129.00 08/28/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184138589
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $32.25 08/28/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184138591
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $193.50 08/28/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184138593
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $161.25 08/28/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184138595
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $32.25 08/28/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184138597
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $96.75 08/28/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184138599
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $495.20 08/28/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184138601
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $495.20 08/28/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184138603
Principal investigator 1 SANOFI US SERVICES INC. $2,725.00 08/25/2025 Non-covered Recipient Entity
The Regents Of The University Of Michigan
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose Ranging Study to Assess the Efficacy, Safety, and Tolerability of Subcutaneous SAR443765 in Adult Participants With Moderate to Severe Asthma No dispute reported 06/30/2026 1226157449
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $224.46 08/21/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184138455
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $28.38 08/21/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184138457
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $37.41 08/21/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184138459
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $33.54 08/21/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184138461
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $28.38 08/21/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184138463
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $37.41 08/21/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184138465
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $25.80 08/21/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184138467
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $77.00 08/21/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184138469
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $37.41 08/21/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184138471
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $33.54 08/21/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184138473
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $33.54 08/21/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184138475
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $50.31 08/21/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184138477
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $37.41 08/21/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184138479
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $37.41 08/21/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184138481
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $45.15 08/21/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184138483
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $25.80 08/21/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184138485
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $32.25 08/21/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184138487
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $77.00 08/21/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184138489
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $45.15 08/21/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184138491
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $37.41 08/21/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184138493
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $33.54 08/21/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184138495
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $33.54 08/21/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184138497
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $37.41 08/21/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184138499
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $25.80 08/21/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184138501
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $28.38 08/21/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184138503
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $50.31 08/21/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184138505
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $45.15 08/21/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184138507
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $32.25 08/21/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184138509
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $224.46 08/21/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184138511
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $37.41 08/21/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184138513
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $37.41 08/21/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184138515
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $37.41 08/21/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184138517
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $33.54 08/21/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184138519
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $33.54 08/21/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184138521
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $28.38 08/21/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184138523
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $50.31 08/21/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184138525
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $37.41 08/21/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184138527
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $45.15 08/21/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184138529
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $25.80 08/21/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184138531
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $37.41 08/21/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184138533
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $77.00 08/21/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184138535
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $32.25 08/21/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184138537
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $25.80 08/21/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184138539
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $37.41 08/21/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184138541
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $50.31 08/21/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184138543
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $28.38 08/21/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184138545
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $33.54 08/21/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184138547
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $33.54 08/21/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184138549
Principal investigator 1 SANOFI US SERVICES INC. $5,390.10 08/11/2025 Non-covered Recipient Entity
The Regents Of The University Of Michigan
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose Ranging Study to Assess the Efficacy, Safety, and Tolerability of Subcutaneous SAR443765 in Adult Participants With Moderate to Severe Asthma No dispute reported 06/30/2026 1226157404
Principal investigator 1 GlaxoSmithKline, LLC. $5,816.70 08/04/2025 Non-covered Recipient Entity
THE REGENTS OF THE UNIVERSITY OF MICHIGAN
A PHASE 3, 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA No dispute reported 06/30/2026 1192165869
Principal investigator 1 SANOFI US SERVICES INC. $44,953.50 08/04/2025 Covered Recipient Teaching Hospital
Univ Of Mi Hospitals & Hlth Ctrs
An Open Label Extension Study to Evaluate the Long-term Safety and Efficacy of Subcutaneous Lunsekimig in Adult Participants With Moderatetosevere Asthma Who Participated in Study DRI16762 No dispute reported 06/30/2026 1226134107
Recipient Regeneron Pharmaceuticals, Inc. $468.75 08/01/2025 Covered Recipient Physician REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184119821
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $495.20 07/28/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184138425
Principal investigator 1 Genentech, Inc. $3,302.00 07/25/2025 Covered Recipient Teaching Hospital
Univ Of Mi Hospitals & Hlth Ctrs
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211560236
Principal investigator 1 GlaxoSmithKline, LLC. $10,504.24 07/23/2025 Non-covered Recipient Entity
THE REGENTS OF THE UNIVERSITY OF MICHIGAN
A PHASE 3, 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA No dispute reported 06/30/2026 1192167042
Principal investigator 1 GENZYME CORPORATION $8,203.00 07/14/2025 Covered Recipient Teaching Hospital
Univ Of Mi Hospitals & Hlth Ctrs
A Randomized, Double-Blind, Placebo Controlled Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Patients With Uncontrolled Moderate to Severe Asthma No dispute reported 06/30/2026 1226134101
Principal investigator 1 SANOFI US SERVICES INC. $8,144.10 07/14/2025 Non-covered Recipient Entity
The Regents Of The University Of Michigan
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose Ranging Study to Assess the Efficacy, Safety, and Tolerability of Subcutaneous SAR443765 in Adult Participants With Moderate to Severe Asthma No dispute reported 06/30/2026 1226157390
Principal investigator 1 Genentech, Inc. $11,180.00 07/09/2025 Covered Recipient Teaching Hospital
Univ Of Mi Hospitals & Hlth Ctrs
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211560233
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $195.31 07/02/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA No dispute reported 06/30/2026 1184138395
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,935.00 07/02/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA No dispute reported 06/30/2026 1184138397
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $270.90 07/02/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA No dispute reported 06/30/2026 1184138399
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $270.90 07/02/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA No dispute reported 06/30/2026 1184138401
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $195.31 07/02/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA No dispute reported 06/30/2026 1184138403
Recipient Regeneron Pharmaceuticals, Inc. $311.12 07/01/2025 Covered Recipient Physician REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184119819
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $224.78 06/30/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184138391
Principal investigator 1 SANOFI US SERVICES INC. $10,125.10 06/23/2025 Non-covered Recipient Entity
The Regents Of The University Of Michigan
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose Ranging Study to Assess the Efficacy, Safety, and Tolerability of Subcutaneous SAR443765 in Adult Participants With Moderate to Severe Asthma No dispute reported 06/30/2026 1226157385
Principal investigator 1 SANOFI US SERVICES INC. $3,365.00 06/23/2025 Non-covered Recipient Entity
The Regents Of The University Of Michigan
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose Ranging Study to Assess the Efficacy, Safety, and Tolerability of Subcutaneous SAR443765 in Adult Participants With Moderate to Severe Asthma No dispute reported 06/30/2026 1226157394
Principal investigator 1 GlaxoSmithKline, LLC. $1,201.50 06/20/2025 Non-covered Recipient Entity
THE REGENTS OF THE UNIVERSITY OF MICHIGAN
A PHASE 3, 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA No dispute reported 06/30/2026 1192165862
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $608.56 06/18/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184138385
Principal investigator 1 SANOFI US SERVICES INC. $6,646.50 06/16/2025 Non-covered Recipient Entity
The Regents Of The University Of Michigan
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose Ranging Study to Assess the Efficacy, Safety, and Tolerability of Subcutaneous SAR443765 in Adult Participants With Moderate to Severe Asthma No dispute reported 06/30/2026 1226157323
Recipient GENZYME CORPORATION $500.00 06/13/2025 Covered Recipient Physician Randomized, Double Blind, Placebo Controlled Study to Evaluate the Effect of Dupilumab on Airway Inflammation Through Assessments of Lung Function, Mucus Plugging and Other Lung Imaging Parameters in Patients With Asthma No dispute reported 06/30/2026 1226119504
Recipient GENZYME CORPORATION $250.00 06/13/2025 Covered Recipient Physician Registry of Asthma Patients Initiating DUPIXENT (RAPID) No dispute reported 06/30/2026 1226119531
Recipient GENZYME CORPORATION $500.00 06/13/2025 Covered Recipient Physician Registry of Asthma Patients Initiating DUPIXENT (RAPID) No dispute reported 06/30/2026 1226119537
Recipient GENZYME CORPORATION $250.00 06/13/2025 Covered Recipient Physician Registry of Asthma Patients Initiating DUPIXENT (RAPID) No dispute reported 06/30/2026 1226119542
Recipient GENZYME CORPORATION $500.00 06/13/2025 Covered Recipient Physician Registry of Asthma Patients Initiating DUPIXENT (RAPID) No dispute reported 06/30/2026 1226119544
Recipient GENZYME CORPORATION $250.00 06/13/2025 Covered Recipient Physician Randomized, Double Blind, Placebo Controlled Study to Evaluate the Effect of Dupilumab on Airway Inflammation Through Assessments of Lung Function, Mucus Plugging and Other Lung Imaging Parameters in Patients With Asthma No dispute reported 06/30/2026 1226119550
Principal investigator 1 Genentech, Inc. $7,080.00 06/04/2025 Covered Recipient Teaching Hospital
Univ Of Mi Hospitals & Hlth Ctrs
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211560114
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $32.25 06/04/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184138373
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $967.50 06/04/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184138375
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,500.00 06/04/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184138377
Recipient Regeneron Pharmaceuticals, Inc. $1,135.00 06/01/2025 Covered Recipient Physician REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184119817
Principal investigator 1 GlaxoSmithKline, LLC. $3,471.30 05/21/2025 Non-covered Recipient Entity
THE REGENTS OF THE UNIVERSITY OF MICHIGAN
A PHASE 3, 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA No dispute reported 06/30/2026 1192163358
Recipient GENZYME CORPORATION $500.00 05/20/2025 Covered Recipient Physician Randomized, Double Blind, Placebo Controlled Study to Evaluate the Effect of Dupilumab on Airway Inflammation Through Assessments of Lung Function, Mucus Plugging and Other Lung Imaging Parameters in Patients With Asthma No dispute reported 06/30/2026 1226119528
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $224.78 05/19/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184138359
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $608.56 05/19/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184138361
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $608.56 05/19/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184138363
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $608.56 05/19/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184138365
Recipient GENZYME CORPORATION $500.00 05/18/2025 Covered Recipient Physician Randomized, Double Blind, Placebo Controlled Study to Evaluate the Effect of Dupilumab on Airway Inflammation Through Assessments of Lung Function, Mucus Plugging and Other Lung Imaging Parameters in Patients With Asthma No dispute reported 06/30/2026 1226119516
Recipient GENZYME CORPORATION $250.00 05/18/2025 Covered Recipient Physician Registry of Asthma Patients Initiating DUPIXENT (RAPID) No dispute reported 06/30/2026 1226119523
Recipient GENZYME CORPORATION $250.00 05/18/2025 Covered Recipient Physician Randomized, Double Blind, Placebo Controlled Study to Evaluate the Effect of Dupilumab on Airway Inflammation Through Assessments of Lung Function, Mucus Plugging and Other Lung Imaging Parameters in Patients With Asthma No dispute reported 06/30/2026 1226119547
Recipient GENZYME CORPORATION $250.00 05/17/2025 Covered Recipient Physician Randomized, Double Blind, Placebo Controlled Study to Evaluate the Effect of Dupilumab on Airway Inflammation Through Assessments of Lung Function, Mucus Plugging and Other Lung Imaging Parameters in Patients With Asthma No dispute reported 06/30/2026 1226119577
Recipient GENZYME CORPORATION $500.00 05/16/2025 Covered Recipient Physician Registry of Asthma Patients Initiating DUPIXENT (RAPID) No dispute reported 06/30/2026 1226119508
Recipient GENZYME CORPORATION $500.00 05/16/2025 Covered Recipient Physician Registry of Asthma Patients Initiating DUPIXENT (RAPID) No dispute reported 06/30/2026 1226119513
Recipient GENZYME CORPORATION $250.00 05/16/2025 Covered Recipient Physician Registry of Asthma Patients Initiating DUPIXENT (RAPID) No dispute reported 06/30/2026 1226119520
Principal investigator 1 AstraZeneca Pharmaceuticals LP $206,968.20 05/14/2025 Covered Recipient Teaching Hospital
Univ Of Mi Hospitals & Hlth Ctrs
Levante A Phase 2b Randomised Double Blind Placebo Controlled Dose Range Finding Study to Assess Efficacy and Safety of Multiple Dose Levels of Inhaled AZD8630 No dispute reported 06/30/2026 1185539673
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $50.31 05/14/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184138269
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $25.80 05/14/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184138271
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $33.54 05/14/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184138273
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $37.41 05/14/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184138275
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $33.54 05/14/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184138277
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $45.15 05/14/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184138279
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $28.38 05/14/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184138281
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $33.54 05/14/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184138283
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $32.25 05/14/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184138285
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $77.00 05/14/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184138287
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $224.46 05/14/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184138289
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $50.31 05/14/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184138291
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $25.80 05/14/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184138293
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $77.00 05/14/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184138295
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $33.54 05/14/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184138297
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $25.80 05/14/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184138299
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $32.25 05/14/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184138301
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $28.38 05/14/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184138303
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $37.41 05/14/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184138305
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $37.41 05/14/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184138307
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $37.41 05/14/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184138309
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $37.41 05/14/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184138311
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $37.41 05/14/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184138313
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $37.41 05/14/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184138315
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $28.38 05/14/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184138317
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $33.54 05/14/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184138319
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $45.15 05/14/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184138321
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $33.54 05/14/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184138323
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $77.00 05/14/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184138325
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $37.41 05/14/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184138327
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $224.46 05/14/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184138329
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $25.80 05/14/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184138331
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $45.15 05/14/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184138333
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $77.00 05/14/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184138335
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $37.41 05/14/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184138337
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $50.31 05/14/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184138339
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $33.54 05/14/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184138341
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $25.80 05/14/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184138343
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $37.41 05/14/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184138345
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $37.41 05/14/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184138347
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $32.25 05/14/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184138349
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $28.38 05/14/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184138351
Principal investigator 1 SANOFI US SERVICES INC. $4,703.40 05/12/2025 Non-covered Recipient Entity
The Regents Of The University Of Michigan
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose Ranging Study to Assess the Efficacy, Safety, and Tolerability of Subcutaneous SAR443765 in Adult Participants With Moderate to Severe Asthma No dispute reported 06/30/2026 1226157307
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $448.92 05/09/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184138259
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $18.06 05/09/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184138261
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $64.50 05/09/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184138263
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $39.99 05/09/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184138265
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $32.25 05/09/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184138267
Principal investigator 1 Genentech, Inc. $3,100.00 05/07/2025 Covered Recipient Teaching Hospital
Univ Of Mi Hospitals & Hlth Ctrs
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211560123
Principal investigator 1 Genentech, Inc. $12,980.00 05/07/2025 Covered Recipient Teaching Hospital
Univ Of Mi Hospitals & Hlth Ctrs
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211560127
Recipient Regeneron Pharmaceuticals, Inc. $937.50 05/01/2025 Covered Recipient Physician ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184119811
Recipient Regeneron Pharmaceuticals, Inc. $915.26 05/01/2025 Covered Recipient Physician REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184119813
Recipient Regeneron Pharmaceuticals, Inc. $1,135.00 05/01/2025 Covered Recipient Physician REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184119815
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $72.24 05/01/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184138243
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $32.25 05/01/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184138245
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $224.46 05/01/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184138247
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $224.46 05/01/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184138249
Principal investigator 1 GENZYME CORPORATION $9,552.00 04/28/2025 Covered Recipient Teaching Hospital
Univ Of Mi Hospitals & Hlth Ctrs
A Randomized, Double-Blind, Placebo Controlled Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Patients With Uncontrolled Moderate to Severe Asthma No dispute reported 06/30/2026 1226134072
Principal investigator 1 GENZYME CORPORATION $2,520.00 04/28/2025 Covered Recipient Teaching Hospital
Univ Of Mi Hospitals & Hlth Ctrs
A Randomized, Double-Blind, Placebo Controlled Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Patients With Uncontrolled Moderate to Severe Asthma No dispute reported 06/30/2026 1226134076
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $270.90 04/28/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA No dispute reported 06/30/2026 1184138223
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $195.31 04/28/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA No dispute reported 06/30/2026 1184138225
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $270.90 04/28/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA No dispute reported 06/30/2026 1184138227
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $12,351.75 04/28/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA No dispute reported 06/30/2026 1184138229
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $495.20 04/28/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184138231
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $495.20 04/28/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184138233
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $495.20 04/28/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184138235
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $495.20 04/28/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184138237
Principal investigator 1 SANOFI US SERVICES INC. $10,487.84 04/28/2025 Non-covered Recipient Entity
The Regents Of The University Of Michigan
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose Ranging Study to Assess the Efficacy, Safety, and Tolerability of Subcutaneous SAR443765 in Adult Participants With Moderate to Severe Asthma No dispute reported 06/30/2026 1226157274
Principal investigator 1 Genentech, Inc. $5,900.00 04/25/2025 Covered Recipient Teaching Hospital
Univ Of Mi Hospitals & Hlth Ctrs
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211560118
Principal investigator 1 GlaxoSmithKline, LLC. $3,824.10 04/23/2025 Non-covered Recipient Entity
THE REGENTS OF THE UNIVERSITY OF MICHIGAN
A PHASE 3, 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA No dispute reported 06/30/2026 1192165852
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $608.56 04/23/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184138203
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $608.56 04/23/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184138205
Principal investigator 1 SANOFI US SERVICES INC. $7,174.80 04/07/2025 Non-covered Recipient Entity
The Regents Of The University Of Michigan
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose Ranging Study to Assess the Efficacy, Safety, and Tolerability of Subcutaneous SAR443765 in Adult Participants With Moderate to Severe Asthma No dispute reported 06/30/2026 1226157239
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $608.56 04/04/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184138193
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $224.78 04/04/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184138195
Principal investigator 1 SANOFI US SERVICES INC. $463.65 04/02/2025 Non-covered Recipient Entity
The Regents Of The University Of Michigan
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose Ranging Study to Assess the Efficacy, Safety, and Tolerability of Subcutaneous SAR443765 in Adult Participants With Moderate to Severe Asthma No dispute reported 06/30/2026 1226157222
Recipient Regeneron Pharmaceuticals, Inc. $309.38 04/01/2025 Covered Recipient Physician REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184119801
Recipient Regeneron Pharmaceuticals, Inc. $416.67 04/01/2025 Covered Recipient Physician REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184119803
Recipient Regeneron Pharmaceuticals, Inc. $292.85 04/01/2025 Covered Recipient Physician REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184119805
Recipient Regeneron Pharmaceuticals, Inc. $60.00 04/01/2025 Covered Recipient Physician DUPIXENT CLINICAL DEVELOPMENT PROGRAM No dispute reported 06/30/2026 1184119807
Recipient Regeneron Pharmaceuticals, Inc. $416.67 04/01/2025 Covered Recipient Physician REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184119809
Principal investigator 1 AstraZeneca Pharmaceuticals LP $48,644.83 03/28/2025 Covered Recipient Teaching Hospital
Univ Of Mi Hospitals & Hlth Ctrs
A Phase 2a Randomised Double-Blind Placebo-Controlled Study to Evaluate the Efficacy and Safety of AZD4604 Twice Daily for Twelve Weeks in Adult Patients with Moderate-to-Severe Asthma Uncontrolled on Medium-High Dose ICS-LABA No dispute reported 06/30/2026 1185539671
Principal investigator 1 SANOFI US SERVICES INC. $7,182.50 03/24/2025 Non-covered Recipient Entity
The Regents Of The University Of Michigan
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose Ranging Study to Assess the Efficacy, Safety, and Tolerability of Subcutaneous SAR443765 in Adult Participants With Moderate to Severe Asthma No dispute reported 06/30/2026 1226157253
Principal investigator 1 Genentech, Inc. $1,651.00 03/21/2025 Covered Recipient Teaching Hospital
Univ Of Mi Hospitals & Hlth Ctrs
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211560029
Principal investigator 1 SANOFI US SERVICES INC. $5,134.50 03/17/2025 Non-covered Recipient Entity
The Regents Of The University Of Michigan
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose Ranging Study to Assess the Efficacy, Safety, and Tolerability of Subcutaneous SAR443765 in Adult Participants With Moderate to Severe Asthma No dispute reported 06/30/2026 1226157235
Principal investigator 1 GENZYME CORPORATION $5,259.82 03/10/2025 Covered Recipient Teaching Hospital
Univ Of Mi Hospitals & Hlth Ctrs
A Randomized, Double-Blind, Placebo Controlled Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Patients With Uncontrolled Moderate to Severe Asthma No dispute reported 06/30/2026 1226134048
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $50.31 03/06/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184138033
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $37.41 03/06/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184138035
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $25.80 03/06/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184138037
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $25.80 03/06/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184138039
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $32.25 03/06/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184138041
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $77.00 03/06/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184138043
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $37.41 03/06/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184138045
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $33.54 03/06/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184138047
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $28.38 03/06/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184138049
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $33.54 03/06/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184138051
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $25.80 03/06/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184138053
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $77.00 03/06/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184138055
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,500.00 03/06/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184138057
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $224.46 03/06/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184138059
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $37.41 03/06/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184138061
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $45.15 03/06/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184138063
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $37.41 03/06/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184138065
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $33.54 03/06/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184138067
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $33.54 03/06/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184138069
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $28.38 03/06/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184138071
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $50.31 03/06/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184138073
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $33.54 03/06/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184138075
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $37.41 03/06/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184138077
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $32.25 03/06/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184138079
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $25.80 03/06/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184138081
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $45.15 03/06/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184138083
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $37.41 03/06/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184138085
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $37.41 03/06/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184138087
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $50.31 03/06/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184138089
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $25.80 03/06/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184138091
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $77.00 03/06/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184138093
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $33.54 03/06/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184138095
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $33.54 03/06/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184138097
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $37.41 03/06/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184138099
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $25.80 03/06/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184138101
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $37.41 03/06/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184138103
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $28.38 03/06/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184138105
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $33.54 03/06/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184138107
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $37.41 03/06/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184138109
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $28.38 03/06/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184138111
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $25.80 03/06/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184138113
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $45.15 03/06/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184138115
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $37.41 03/06/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184138117
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $37.41 03/06/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184138119
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $50.31 03/06/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184138121
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $28.38 03/06/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184138123
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $33.54 03/06/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184138125
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $33.54 03/06/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184138127
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $77.00 03/06/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184138129
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $32.25 03/06/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184138131
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $25.80 03/06/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184138133
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $45.15 03/06/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184138135
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $37.41 03/06/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184138137
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $37.41 03/06/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184138139
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $50.31 03/06/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184138141
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $33.54 03/06/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184138143
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $37.41 03/06/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184138145
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $32.25 03/06/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184138147
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $224.46 03/06/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184138149
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $28.38 03/06/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184138151
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $37.41 03/06/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184138153
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $33.54 03/06/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184138155
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $37.41 03/06/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184138157
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $45.15 03/06/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184138159
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $37.41 03/06/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184138161
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $28.38 03/06/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184138163
Recipient GENZYME CORPORATION $500.00 03/01/2025 Covered Recipient Physician Registry of Asthma Patients Initiating DUPIXENT (RAPID) No dispute reported 06/30/2026 1226119483
Recipient GENZYME CORPORATION $250.00 03/01/2025 Covered Recipient Physician Registry of Asthma Patients Initiating DUPIXENT (RAPID) No dispute reported 06/30/2026 1226119487
Recipient GENZYME CORPORATION $500.00 03/01/2025 Covered Recipient Physician Registry of Asthma Patients Initiating DUPIXENT (RAPID) No dispute reported 06/30/2026 1226119494
Recipient GENZYME CORPORATION $250.00 03/01/2025 Covered Recipient Physician Randomized, Double Blind, Placebo Controlled Study to Evaluate the Effect of Dupilumab on Airway Inflammation Through Assessments of Lung Function, Mucus Plugging and Other Lung Imaging Parameters in Patients With Asthma No dispute reported 06/30/2026 1226119498
Recipient GENZYME CORPORATION $250.00 03/01/2025 Covered Recipient Physician Randomized, Double Blind, Placebo Controlled Study to Evaluate the Effect of Dupilumab on Airway Inflammation Through Assessments of Lung Function, Mucus Plugging and Other Lung Imaging Parameters in Patients With Asthma No dispute reported 06/30/2026 1226119581
Recipient GENZYME CORPORATION $500.00 03/01/2025 Covered Recipient Physician Randomized, Double Blind, Placebo Controlled Study to Evaluate the Effect of Dupilumab on Airway Inflammation Through Assessments of Lung Function, Mucus Plugging and Other Lung Imaging Parameters in Patients With Asthma No dispute reported 06/30/2026 1226119585
Recipient Regeneron Pharmaceuticals, Inc. $915.26 03/01/2025 Covered Recipient Physician REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184119797
Recipient Regeneron Pharmaceuticals, Inc. $915.26 03/01/2025 Covered Recipient Physician REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184119799
Recipient GENZYME CORPORATION $250.00 02/28/2025 Covered Recipient Physician Registry of Asthma Patients Initiating DUPIXENT (RAPID) No dispute reported 06/30/2026 1226119589
Principal investigator 1 Genentech, Inc. $17,690.00 02/28/2025 Covered Recipient Teaching Hospital
Univ Of Mi Hospitals & Hlth Ctrs
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211560025
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $608.56 02/27/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184138027
Principal investigator 1 Genentech, Inc. $950.00 02/26/2025 Covered Recipient Teaching Hospital
Univ Of Mi Hospitals & Hlth Ctrs
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211560033
Principal investigator 1 GlaxoSmithKline, LLC. $6,135.30 02/25/2025 Non-covered Recipient Entity
THE REGENTS OF THE UNIVERSITY OF MICHIGAN
A PHASE 3, 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA No dispute reported 06/30/2026 1192167027
Principal investigator 1 AstraZeneca Pharmaceuticals LP $44,783.72 02/24/2025 Covered Recipient Teaching Hospital
Univ Of Mi Hospitals & Hlth Ctrs
A Multicenter,Single arm,Open label,Post Authorization,Phase 4 Effectiveness and Safety Study of Tezepelumab in Adult and Adolescent Participants with Severe Asthma including Several Under Studied Populations in the United States No dispute reported 06/30/2026 1185539669
Principal investigator 1 Genentech, Inc. $54,483.00 02/21/2025 Covered Recipient Teaching Hospital
Univ Of Mi Hospitals & Hlth Ctrs
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211560037
Principal investigator 1 AstraZeneca Pharmaceuticals LP $27,496.20 02/19/2025 Covered Recipient Teaching Hospital
Univ Of Mi Hospitals & Hlth Ctrs
A Multicenter Open label Phase 3B Efficacy and Safety Study of Tezepelumab 210 mg Administered Subcutaneously to Reduce Oral Corticosteroid Use and Asthma Exacerbations in Adult Subjects with Severe Asthma on High Dose Inhaled Corticosteroid plus Long acting B2 Agonist and Chronic Oral Corticosteroid Therapy No dispute reported 06/30/2026 1185539667
Principal investigator 1 SANOFI US SERVICES INC. $25,362.00 02/18/2025 Non-covered Recipient Entity
The Regents Of The University Of Michigan
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose Ranging Study to Assess the Efficacy, Safety, and Tolerability of Subcutaneous SAR443765 in Adult Participants With Moderate to Severe Asthma No dispute reported 06/30/2026 1226157226
Principal investigator 1 SANOFI US SERVICES INC. $2,937.65 02/18/2025 Non-covered Recipient Entity
The Regents Of The University Of Michigan
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose Ranging Study to Assess the Efficacy, Safety, and Tolerability of Subcutaneous SAR443765 in Adult Participants With Moderate to Severe Asthma No dispute reported 06/30/2026 1226157230
Recipient GENZYME CORPORATION $1,250.00 02/10/2025 Covered Recipient Physician Randomized, Double Blind, Placebo Controlled Study to Evaluate the Effect of Dupilumab on Airway Inflammation Through Assessments of Lung Function, Mucus Plugging and Other Lung Imaging Parameters in Patients With Asthma No dispute reported 06/30/2026 1226119501
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $224.78 02/05/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184137987
Principal investigator 1 GENZYME CORPORATION $7,519.28 02/04/2025 Covered Recipient Teaching Hospital
Univ Of Mi Hospitals & Hlth Ctrs
A Randomized, Double-Blind, Placebo Controlled Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Patients With Uncontrolled Moderate to Severe Asthma No dispute reported 06/30/2026 1226134051
Principal investigator 1 SANOFI US SERVICES INC. $4,847.30 02/04/2025 Non-covered Recipient Entity
The Regents Of The University Of Michigan
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose Ranging Study to Assess the Efficacy, Safety, and Tolerability of Subcutaneous SAR443765 in Adult Participants With Moderate to Severe Asthma No dispute reported 06/30/2026 1226157176
Recipient Regeneron Pharmaceuticals, Inc. $416.67 02/01/2025 Covered Recipient Physician REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184119789
Recipient Regeneron Pharmaceuticals, Inc. $353.57 02/01/2025 Covered Recipient Physician REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184119791
Recipient Regeneron Pharmaceuticals, Inc. $416.67 02/01/2025 Covered Recipient Physician REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184119793
Recipient Regeneron Pharmaceuticals, Inc. $353.57 02/01/2025 Covered Recipient Physician REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184119795
Principal investigator 1 Genentech, Inc. $19,812.00 01/31/2025 Covered Recipient Teaching Hospital
Univ Of Mi Hospitals & Hlth Ctrs
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211560045
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $495.20 01/31/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184137985
Principal investigator 1 SANOFI US SERVICES INC. $8,600.00 01/27/2025 Covered Recipient Teaching Hospital
Univ Of Mi Hospitals & Hlth Ctrs
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose Ranging Study to Assess the Efficacy, Safety, and Tolerability of Subcutaneous Amlitelimab in Adult Participants With Moderate-to-severe Asthma No dispute reported 06/30/2026 1226134033
Principal investigator 1 SANOFI US SERVICES INC. $1,935.00 01/27/2025 Covered Recipient Teaching Hospital
Univ Of Mi Hospitals & Hlth Ctrs
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose Ranging Study to Assess the Efficacy, Safety, and Tolerability of Subcutaneous Amlitelimab in Adult Participants With Moderate-to-severe Asthma No dispute reported 06/30/2026 1226134038
Principal investigator 1 GlaxoSmithKline, LLC. $7,907.40 01/24/2025 Non-covered Recipient Entity
THE REGENTS OF THE UNIVERSITY OF MICHIGAN
A PHASE 3, 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA No dispute reported 06/30/2026 1192167017
Principal investigator 1 AstraZeneca Pharmaceuticals LP $217,804.38 01/23/2025 Covered Recipient Teaching Hospital
Univ Of Mi Hospitals & Hlth Ctrs
The CHRONICLE Study is a multi center,non interventional,prospective cohort study of adults with severe asthma who do not achieve control with high-dose ICS therapy with additional controllers and or require systemic corticosteroid or monoclonal antibod No dispute reported 06/30/2026 1185551147
Recipient Amgen Inc. $7,896.00 01/22/2025 Covered Recipient Physician Asthma Biologics Across the T2 Spectrum of Inflammation in Severe Asthma: Biomarkers and Mechanism of Action No dispute reported 06/30/2026 1246637096
Principal investigator 1 Genentech, Inc. $16,510.00 01/22/2025 Covered Recipient Teaching Hospital
Univ Of Mi Hospitals & Hlth Ctrs
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211560048
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $224.78 01/15/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184137973
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $224.78 01/15/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184137975
Principal investigator 1 Genentech, Inc. $49,530.00 01/13/2025 Covered Recipient Teaching Hospital
Univ Of Mi Hospitals & Hlth Ctrs
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211560041
Principal investigator 1 AstraZeneca Pharmaceuticals LP $126,257.04 01/10/2025 Covered Recipient Teaching Hospital
Univ Of Mi Hospitals & Hlth Ctrs
A Phase 4 Multicenter Randomized Double blind Parallel Group Placebo controlled Study to Evaluate the Effect of Benralizumab on Structural and Lung Function Changes in Severe Eosinophilic Asthmatics (CHINOOK) No dispute reported 06/30/2026 1185539661
Principal investigator 1 AstraZeneca Pharmaceuticals LP $26,138.20 01/08/2025 Covered Recipient Teaching Hospital
Univ Of Mi Hospitals & Hlth Ctrs
A Randomised, Double-blind, Active-controlled 52-week Study with an Open-label Extension to Evaluate the Efficacy and Safety of Benralizumab Compared to Mepolizumab in the Treatment of Eosinophilic Granulomatosis with Polyangiitis (EGPA) in Patients Receiving Standard of Care Therapy No dispute reported 06/30/2026 1185539663
Principal investigator 1 GlaxoSmithKline, LLC. $4,886.90 01/08/2025 Non-covered Recipient Entity
THE REGENTS OF THE UNIVERSITY OF MICHIGAN
A PHASE 3, 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA No dispute reported 06/30/2026 1192165855
Principal investigator 1 GlaxoSmithKline, LLC. $97.00 01/08/2025 Non-covered Recipient Entity
THE REGENTS OF THE UNIVERSITY OF MICHIGAN
A PHASE 3, 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA No dispute reported 06/30/2026 1192167023
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $37.41 01/08/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184137793
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $37.41 01/08/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184137795
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $50.31 01/08/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184137797
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $25.80 01/08/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184137799
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $28.38 01/08/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184137801
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $33.54 01/08/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184137803
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $33.54 01/08/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184137805
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $37.41 01/08/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184137807
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $77.00 01/08/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184137809
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $25.80 01/08/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184137811
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $37.41 01/08/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184137813
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $28.38 01/08/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184137815
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $33.54 01/08/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184137817
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $33.54 01/08/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184137819
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $37.41 01/08/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184137821
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $77.00 01/08/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184137823
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $25.80 01/08/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184137825
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $37.41 01/08/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184137827
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $28.38 01/08/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184137829
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $77.00 01/08/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184137831
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $77.00 01/08/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184137833
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $77.00 01/08/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184137835
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $77.00 01/08/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184137837
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $77.00 01/08/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184137839
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $32.25 01/08/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184137841
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $25.80 01/08/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184137843
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $45.15 01/08/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184137845
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $37.41 01/08/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184137847
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $37.41 01/08/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184137849
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $50.31 01/08/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184137851
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $25.80 01/08/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184137853
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $33.54 01/08/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184137855
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $33.54 01/08/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184137857
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $37.41 01/08/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184137859
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $77.00 01/08/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184137861
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $77.00 01/08/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184137863
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $77.00 01/08/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184137865
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $77.00 01/08/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184137867
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $77.00 01/08/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184137869
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $77.00 01/08/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184137871
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $77.00 01/08/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184137873
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $77.00 01/08/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184137875
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $33.54 01/08/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184137877
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $77.00 01/08/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184137879
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $32.25 01/08/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184137881
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $77.00 01/08/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184137883
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $33.54 01/08/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184137885
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $77.00 01/08/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184137887
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $37.41 01/08/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184137889
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $33.54 01/08/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184137891
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $77.00 01/08/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184137893
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $77.00 01/08/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184137895
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $32.25 01/08/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184137897
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $25.80 01/08/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184137899
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $45.15 01/08/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184137901
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $77.00 01/08/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184137903
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $77.00 01/08/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184137905
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $37.41 01/08/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184137907
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $33.54 01/08/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184137909
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $28.38 01/08/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184137911
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $50.31 01/08/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184137913
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $37.41 01/08/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184137915
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $37.41 01/08/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184137917
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $77.00 01/08/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184137919
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $25.80 01/08/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184137921
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $45.15 01/08/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184137923
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $37.41 01/08/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184137925
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $37.41 01/08/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184137927
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $50.31 01/08/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184137929
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $28.38 01/08/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184137931
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $33.54 01/08/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184137933
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $33.54 01/08/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184137935
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $37.41 01/08/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184137937
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $77.00 01/08/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184137939
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $77.00 01/08/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184137941
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $77.00 01/08/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184137943
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $77.00 01/08/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184137945
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $77.00 01/08/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184137947
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $28.38 01/08/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184137949
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $224.46 01/08/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184137951
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $224.46 01/08/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184137953
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $77.00 01/08/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184137955
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $32.25 01/08/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184137957
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $45.15 01/08/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184137959
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $77.00 01/08/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184137961
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $77.00 01/08/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184137963
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $77.00 01/08/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184137965
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $77.00 01/08/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184137967
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $224.78 01/02/2025 Covered Recipient Teaching Hospital
UNIV OF MI HOSPITALS & HLTH CTRS
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184137787